The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
B. Chibaudel
No relevant relationships to disclose
C. Tournigand
No relevant relationships to disclose
M. Mabro
No relevant relationships to disclose
M. Bennamoun
No relevant relationships to disclose
P. Artru
Honoraria - Amgen
S. Nguyen
No relevant relationships to disclose
J. Bachet
No relevant relationships to disclose
N. Aissat
No relevant relationships to disclose
H. Blons
No relevant relationships to disclose
P. Laurent-Puig
Research Funding - Amgen
A. De Gramont
Research Funding - Amgen
T. Andre
Honoraria - Amgen
Research Funding - Amgen